Your browser doesn't support javascript.
loading
Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
Lacour, A; Espinosa, A; Louwersheimer, E; Heilmann, S; Hernández, I; Wolfsgruber, S; Fernández, V; Wagner, H; Rosende-Roca, M; Mauleón, A; Moreno-Grau, S; Vargas, L; Pijnenburg, Y A L; Koene, T; Rodríguez-Gómez, O; Ortega, G; Ruiz, S; Holstege, H; Sotolongo-Grau, O; Kornhuber, J; Peters, O; Frölich, L; Hüll, M; Rüther, E; Wiltfang, J; Scherer, M; Riedel-Heller, S; Alegret, M; Nöthen, M M; Scheltens, P; Wagner, M; Tárraga, L; Jessen, F; Boada, M; Maier, W; van der Flier, W M; Becker, T; Ramirez, A; Ruiz, A.
Afiliação
  • Lacour A; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Espinosa A; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Louwersheimer E; Department of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Heilmann S; Institute of Human Genetics, University of Bonn, Bonn, Germany.
  • Hernández I; Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany.
  • Wolfsgruber S; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Fernández V; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Wagner H; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
  • Rosende-Roca M; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Mauleón A; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
  • Moreno-Grau S; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Vargas L; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Pijnenburg YA; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Koene T; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Rodríguez-Gómez O; Department of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Ortega G; Department of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Ruiz S; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Holstege H; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Sotolongo-Grau O; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Kornhuber J; Alzheimer Center and Department of Clinical Genetics, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Peters O; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Frölich L; Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Hüll M; Department of Psychiatry, Charité University Medicine, Berlin, Germany.
  • Rüther E; Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Wiltfang J; Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany.
  • Scherer M; Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
  • Riedel-Heller S; Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
  • Alegret M; Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Nöthen MM; Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.
  • Scheltens P; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Wagner M; Institute of Human Genetics, University of Bonn, Bonn, Germany.
  • Tárraga L; Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany.
  • Jessen F; Department of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Boada M; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Maier W; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
  • van der Flier WM; Memory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
  • Becker T; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Ramirez A; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
  • Ruiz A; Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany.
Mol Psychiatry ; 22(1): 153-160, 2017 01.
Article em En | MEDLINE | ID: mdl-26976043
ABSTRACT
Few data are available concerning the role of risk markers for Alzheimer's disease (AD) in progression to AD dementia among subjects with mild cognitive impairment (MCI). We therefore investigated the role of well-known AD-associated single-nucleotide polymorphism (SNP) in the progression from MCI to AD dementia. Four independent MCI data sets were included in the

analysis:

(a) the German study on Aging, Cognition and Dementia in primary care patients (n=853); (b) the German Dementia Competence Network (n=812); (c) the Fundació ACE from Barcelona, Spain (n=1245); and (d) the MCI data set of the Amsterdam Dementia Cohort (n=306). The effects of single markers and combined polygenic scores were measured using Cox proportional hazards models and meta-analyses. The clusterin (CLU) locus was an independent genetic risk factor for MCI to AD progression (CLU rs9331888 hazard ratio (HR)=1.187 (1.054-1.32); P=0.0035). A polygenic score (PGS1) comprising nine established genome-wide AD risk loci predicted a small effect on the risk of MCI to AD progression in APOE-ɛ4 (apolipoprotein E-ɛ4) carriers (HR=1.746 (1.029-2.965); P=0.038). The novel AD loci reported by the International Genomics of Alzheimer's Project were not implicated in MCI to AD dementia progression. SNP-based polygenic risk scores comprising currently available AD genetic markers did not predict MCI to AD progression. We conclude that SNPs in CLU are potential markers for MCI to AD progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha